TOMEGAVAX, INC.
Biotech · Acquired
CMV-vectored therapeutic vaccine for chronic hepatitis B using engineered viral vectors and algorithm-designed antigens
- Grants
- $7.1M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · A human cytomegalovirus-based immunotherapy for HIV-1 | $986,519 | |
| Federal grant | Department of Health and Human Services · Phase I · A Cytomegalovirus Vectored Chagas Disease Therapeutic Vaccine | $224,959 | |
| Federal grant | Department of Health and Human Services · Phase II · A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses | $948,184 | |
| Federal grant | Department of Health and Human Services · Phase II · A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B | $297,434 | |
| Federal grant | Department of Health and Human Services · Phase II · A human cytomegalovirus-based immunotherapy for HIV-1 | $986,188 | |
| Federal grant | Department of Health and Human Services · Phase II · A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses | $928,329 | |
| Federal grant | Department of Health and Human Services · Phase II · A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B | $1,685,089 | |
| Federal grant | Department of Health and Human Services · Phase II · A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1297 | MEDIKINE INC | — | — |
| 1298 | NANGIOTX, INC. | — | — |
| 1299 | Seres Therapeutics | — | — |
| 1300 | TOMEGAVAX, INC. | — | — |
| 1301 | Windward Bio | — | — |
| 1302 | Azalea Therapeutics | — | — |
| 1303 | Maze Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.